Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

8.30

Mkt cap

282M

Volume

19K

High

8.45

P/E Ratio

-4.52

52-wk high

20.00

Low

8.22

Div yield

N/A

52-wk low

4.00

Nyxoah S.A. (NYXH) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Olivier Taelman and CFO Loic Moreau, with analysts from Piper Sandler, Stifel, Oppenheimer, Cantor Fitzgerald, and Baird attending.

Portfolio Pulse from

November 09, 2024 | 12:00 am

Nyxoah SA (NYXH) reported a Q3 loss of $0.68 per share, which was larger than the Zacks Consensus Estimate of a $0.46 loss. However, the company exceeded revenue expectations.

Portfolio Pulse from

November 07, 2024 | 1:30 am

Nyxoah SA has appointed John Landry as the new Chief Financial Officer, with the current CFO, Loïc Moreau, transitioning to President International. This move, along with the CEO's recent relocation to the U.S., highlights Nyxoah's strategic focus on the U.S. market.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

HC Wainwright & Co. has maintained a Buy rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $18 to $17.